Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated…

The Economic Times

Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year

After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors.

International Business Times

The New Drug Melting Body Fat From 38% To 22% — And The Side Effect Patients Are Ignoring

A new weight loss drug is drawing serious attention from the medical community, and the comparisons to Ozempic are coming quickly. But researchers are pointing to one difference between the two that is proving difficult to overlook, and it may change how the conversation around weight loss medication develops from…

Bored Panda

From analysis to the latest developments in health,
read the most diverse news in one place.

The First Oral GLP-1 Weight Loss Pill With No Food or Injection Requirements Is Now Available

Eli Lilly's Foundayo (orforglipron) is the first oral GLP-1 obesity pill with no food or water restrictions. FDA approved it April 1, 2026. Here is what patients should know.

Medical Daily

Insider Moves Are Sending Mixed Signals Across the Tech Sector

Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares.

MarketBeat

Two weight-loss drugmakers in legal battle over which is most effective in helping users shed pounds

Novo Nordisk claims Eli Lilly compared peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50-pound weight loss versus 33 pounds

The Independent UK

Novo Nordisk Says Eli Lilly Used Misleading Weight Loss Drug Advertising. It's Suing

The lawsuit, filed Tuesday, alleges that Eli Lilly violated federal and state false advertising laws by promoting "knowingly outdated clinical trial" results that compare both companies' drugs.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its drugs with higher doses of Lilly's. Lilly's advertisements allegedly omit newer, higher-dose versions of Novo's medicines. Novo seeks to withdraw…

The Economic Times

Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

Kiplinger

Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition

Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion.

International Business Times

Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock

Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.

Barchart

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes AtaiBeckley's lead candidate, BPL-003, a nasal spray. This move follows increased interest in psychedelic therapies and federal funding for research. The companies expect…

The Economic Times

‘A new consumer’: how weight-loss drugs are shaking up clothes shopping

As they slim down, UK and US users of GLP-1 jabs and pills are changing their spending habits – and their wardrobes

The Guardian - UK

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

A New FDA-Approved Oral Weight Loss Pill Requires No Fasting: What Makes Foundayo Different from Other GLP-1 Drugs

FDA approved Foundayo (orforglipron) on April 1, 2026 — the only oral GLP-1 pill for weight loss you can take any time of day without fasting. Average weight loss: 12.4%. Here's the breakdown.

The Guardian - UK

Wegovy weight-loss pill goes on sale on UK high street and online pharmacies

Thousands of people begin receiving their first deliveries of once-a-day medication made by Novo Nordisk

Fortune

Eli Lilly just placed a $40 million bet on the next injectable boom

The GLP-1 maker’s latest AI investment targets drug discovery and the future of consumer medicine.

The Independent UK

Medicare will soon cover costs of weight-loss drugs. Here’s what you can expect to pay.

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Six Underrated Stocks Britain's Top Fund Managers Believe Could Deliver Long-Term Growth

Six top fund managers reveal their favourite under-the-radar investments in healthcare, finance, retail, energy, and consumer goods with long-term growth potential despite risks.

International Business Times UK

'He's Such a Fraud': Trump Cakes Bruised Hands in Makeup as Solon Demands Answers Over 'Terminal Illness' Rumours

Donald Trump's bruised hands, visible in new Oval Office photos, have fuelled uneasy questions about his health after he abruptly cancelled a bipartisan housing bill signing.

International Business Times UK

Did Trump Get Experimental Obesity Drug? Rep Lieu Demands Answers Over FDA's 'Powerful Drug' Given to 'Unidentified 79-Year-Old Man'

Representative Ted Lieu questions the White House about claims that President Trump accessed an experimental obesity drug reserved for the gravely ill, sparking controversy and speculation.

International Business Times UK

What Is Retatrutide? The Experimental Weight Loss Drug Millions Cannot Access, But Has Sparked a White House Meltdown Over Trump's Health

A 79-year-old man's access to the experimental drug Retatrutide through the FDA's Expanded Access programme has sparked controversy, with allegations of political insider influence and White House denials.

International Business Times UK

Trump Linked to Mystery FDA Deal Granting Early Access to Powerful Weight-Loss Drug for Critical Patients

A 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide, sparking political and medical controversy amid speculation about the patient's identity.

The Independent UK

White House denies Trump is the ‘well-connected’ man who gained compassionate access to obesity drug in April

A White House spokesman said theories that President Trump sought the drug were ‘baseless speculation’

Fortune

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion

“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine, tells Fortune.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.